alexa Have we gone too far? Endovascular stent-graft repair of aortobronchial fistulas.


Journal of Antivirals & Antiretrovirals

Author(s): Wheatley GH rd, Nunez A, Preventza O, Ramaiah VG, RodriguezLopez JA,

Abstract Share this page

Abstract OBJECTIVE: Although endovascular repair of the descending thoracic aorta has emerged as a viable treatment option, little is known about its potential to treat patients diagnosed with aortobronchial fistulas. We reviewed our comprehensive thoracic endografting experience with regard to the endovascular management and subsequent outcome of patients with aortobronchial fistulas to assess whether endoluminal graft repair is a realistic option. METHODS: Between February 2000 and November 2005, 255 patients were successfully treated with an endoluminal graft to the descending thoracic aorta. Indications for intervention included: atherosclerotic aneurysms (109/255, 42.7\%), acute and chronic dissections (75/255, 29.4\%), miscellaneous (34/255, 13.3\%), penetrating aortic ulcers (30/255, 11.8\%), and aortobronchial fistulas (7/255, 2.7\%). RESULTS: Average patient age was 73.4 +/- 10.1 years, with 4 male patients (4/7, 57.1\%) and 3 female patients (3/7, 42.9\%). All patients presented with hemoptysis, with 1 patient (1/7, 14.3\%) requiring preoperative blood transfusion. Three patients (3/7, 42.9\%) were diagnosed with atherosclerotic aneurysms, 3 patients (3/7, 42.9\%) had pseudoaneurysms associated with prior open surgical repair, and 1 patient (1/7, 14.3\%) had a prior endoluminal graft placed for a traumatic aortic transection. No standard postoperative antibiotic regimen was followed. There were no endoleaks, no incidences of paraplegia, and no endoluminal graft infections. Survival was 100\% (7/7) at both 30 days and 1 year, and all patients are currently alive. Follow-up computed tomography was available for all 7 patients, with an average follow-up of 42.6 +/- 28.5 months. CONCLUSIONS: Endovascular management of aortobronchial fistulas appears to be safe and well tolerated, even in surgically high-risk patients, with minimal risk of prosthesis infection. Long-term surveillance and continued investigation are warranted. This article was published in J Thorac Cardiovasc Surg and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version